semaglutide long acting (SYH9017)
/ CSPC Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 06, 2025
The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity
(clinicaltrials.gov)
- P1 | N=66 | Recruiting | Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Genetic Disorders • Obesity
1 to 1
Of
1
Go to page
1